Cell Therapeutics, Inc.Seattle, WA United States
Company Description
Cell Therapeutics (CTI) is a toxic avenger. The firm creates more effective and less toxic treatments for various forms of cancer. CTI is developing a number of cancer-fighting compounds, including pixantrone, a treatment for non-Hodgkin's lymphoma and other tumorous cancers, and Opaxio (paclitaxel poliglumex) for non-small cell lung and ovarian cancers. The company's Systems Medicine subsidiary is working on a potential sarcoma-fighter called brostallicin. CTI no longer markets any commercial products and instead focuses on research and development projects.
| 501 Elliott Ave. West, Ste. 400 | Phone: 206-282-7100 | http://www.cticseattle.com |
| Seattle, WA 98119 | Fax: 206-284-6206 | 
Map This Company |
| United States | Toll Free: 800-215-2355 |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
Cell Therapeutics, Inc. Rankings
| Russell 2000 (June 2011) |
Executives
| 25 executives listed for Cell Therapeutics, Inc.'s Seattle, WA location. | ||
| Chairman | Phillip Nudelman | |
|---|---|---|
| CEO and Director | James Bianco | |
| EVP Finance and Administration | LouisBianco | |
Financials
| Company Type | Public - NASDAQ: CTIC Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 95 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Cell Therapeutics, Inc. now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
